Delcath Systems, Inc. (DCTH) stock
Close on Nov 11, 2026Market cap $755.39MP/E 136.1Yield –
Delcath Systems, Inc. grew revenue 38.1% to $109.96M over the twelve months to Sep 30, 2026. Operating income fell 3.3% to $5.69M, moving the operating margin from 7.4% to 5.2%. Free cash flow was $20.11M, up 67.1% from a year earlier. At the latest close the market valued the company at $755.39M, 136.1 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $755.39M
- P/E ratio
- 136.1
- Price to sales
- 6.87
- Price to book
- 5.66
- Dividend yield
- –
- Free cash flow yield
- 2.66%
Fundamentals
- Revenue
- $109.96M
- Net income
- $6.65M
- EPS, diluted
- $0.16
- Free cash flow
- $20.11M
- Book value per share
- $3.26
- Diluted shares
- 41M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $20.10
- Open
- $20.52
- Day's range
- $20.29 – $22.33
- Volume
- 2,017,292
- Average volume (20 days)
- 690,481
- Index membership
- Russell 2000 (since Jun 2025)
- Beta (5 years)
- 1.10
- 52-week range
- $8.12 – $22.33
- RSI (14 days)
- 81.6
- Volatility (1 year)
- 61.2%
- Relative volume
- 4.09×
- WACC
- 10.4%
On 1 of our idea list: Breakout quarter
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | DCTH | S&P 500 | Difference | DCTH per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +41.7% | -2.4% | +44.1 pts | ||
| 3 months | +26.4% | -1.2% | +27.6 pts | ||
| Year to date | +115.5% | +12.3% | +103.3 pts | ||
| 1 year | +152.6% | +12.4% | +140.1 pts | ||
| 3 years | +638.0% | +78.8% | +559.2 pts | +94.7% | +21.4% |
| 5 years | +101.3% | +75.2% | +26.1 pts | +15.0% | +11.9% |
| 10 years | -98.3% | +311.1% | −409.4 pts | -33.6% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Delcath Systems filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Results
- Results
About Delcath Systems
Surgical & Medical Instruments & Apparatus
Delcath Systems, Inc. is an interventional oncology company that specializes in treatments for primary and metastatic liver cancers. The company operates through a single business segment and develops liver-directed therapies designed to administer chemotherapy directly to the liver while restricting systemic exposure. Its primary commercial offerings include the HEPZATO KIT, an FDA-approved drug and device combination, and CHEMOSAT, a stand-alone hepatic delivery medical device marketed in Europe. Delcath provides these systems primarily to specialized cancer centers, hospital radiology departments, and treating oncologists caring for adult cancer patients.
Company profile, executives and historyDelcath Systems stock: common questions
What is Delcath Systems's stock price?
DCTH closed at $21.77 on Nov 11, 2026, up 8.31% on the day. Over the past 52 weeks it traded between $8.12 and $22.33.
What is Delcath Systems's market cap?
Delcath Systems was worth $755.39M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is DCTH's P/E ratio?
DCTH trades at 136.1 times earnings, based on diluted earnings per share of $0.16 over the twelve months to Sep 30, 2026.
How much revenue does Delcath Systems make?
Delcath Systems reported revenue of $109.96M for the twelve months to Sep 30, 2026, up 38.1% from a year earlier.
Does Delcath Systems pay a dividend?
No. Delcath Systems has not paid a cash dividend over the last twelve months.
When does Delcath Systems report earnings next?
Delcath Systems is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has DCTH stock performed over the past year?
Including dividends, DCTH returned +152.6% over the past year, against +12.4% for the S&P 500.
How many DCTH shares are sold short?
2M shares were sold short at the latest FINRA report, 8.18% of the float, or 5.7 days of average trading volume.
Who are Delcath Systems's competitors?
Companies most similar to Delcath Systems by business, industry and size include ANGO, TLSI, INFU, LUNG, IRMD.
See a number that looks wrong?